
In the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...
Czytaj więcejVisit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...
Czytaj więcejWe would like to invite you to the 23rd Kapras Day on the topic of "Clinical Genetics," which will take place on Wednesday, February 26, 2025, in the Congress Hall of Hotel Olšanka in Prague. We loo...
Czytaj więcejDescription
Nerve Growth Factor (NGF) holds great therapeutic promise for Alzheimer's disease, diabetic neuropathies, ophthalmic diseases, and dermatological ulcers. However, the necessity for systemic delivery has hampered the clinical applications of NGF due to its potent pro-nociceptive action. A "painless" human NGF (hNGF R100W) mutant has been engineered. It has equal neurotrophic potency to hNGF but a lower nociceptive activity.
Full Name
Human NGF R100W Mutant
Source
E. coli
Species
Human
Accession #
CAA36832
Molecule Weight
The 120 amino acid recombinant protein has a predicted molecular mass of approximately 13.5 kD as monomer.
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Applications
ELISA, Functional Assay
Activity
Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is typically 0.2-2 ng/ml.
Storage
-80°C, avoid repeated freeze-thaw cycles.
Storage Buffer
PBS